WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Life Sciences

Open PDF
  • One of the Largest Life Sciences Practices in the U.S.

    Wilson Sonsini's Life Sciences practice is one of the largest in the U.S., with an inter-disciplinary team of more than 275 attorneys, patent agents, and IP professionals.

  • Our Attorneys Act as Strategic General Counsel, Advising on a Comprehensive Scope of Business Operations and Issues

    Wilson Sonsini's attorneys often act as strategic general counsel, drawing from their broader scope of experience and advising on matters beyond patents and IP. 

  • A Nationally Recognized and Ranked Life Sciences Practice

    Wilson Sonsini was recognized as a “Leading Firm” for Life Sciences—in the Nationwide, California, and Massachusetts categories—in the 2026 edition of Chambers USA. The firm was ranked Tier 1 for Venture Capital and Tier 2 for Corporate Life Sciences in the 2025 LMG Life Sciences guide. Wilson Sonsini has been named a finalist for “Licensing and Collaboration Firm of the Year,” “Venture Capital Firm of the Year,” and “Hatch-Waxman Litigation Firm of the Year (Generic),” as part of the 2026 LMG Life Sciences Awards.

A Legacy of Life Sciences Leadership

The firm has a 60-plus year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients.

Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry. A central pillar of our Life Sciences practice is our longstanding representation of medical device and biopharmaceutical companies, entrepreneurs, and investors, which dates back to these industries’ inception.

Wilson Sonsini’s Life Sciences practice is anchored by an inter-disciplinary team of more than 275 attorneys, patent agents, and IP professionals, many of whom hold possess Ph.Ds or other advanced degrees in biology, chemistry, biomedical sciences, or engineering. The team also includes former in-house legal counsel for major life sciences companies, an internationally recognized leader in the field of technology transfer, and former senior officials at U.S. federal agencies, such as the U.S. Patent and Trademark Office (USPTO) and the Patent Trial and Appeal Board (PTAB).

Key Points About Our Practice

On behalf of our life sciences clients, Wilson Sonsini:

  • Acted as trusted advisors to 1,800+ private and 170+ publicly traded life sciences companies
  • Completed hundreds of public offerings and M&A transactions with a combined value of more than $122.5 billion between 2020-2025
  • Raised 1,500+ venture rounds totaling over $38.1 billion
  • Counseled hundreds of life sciences companies on structuring strategic commercial collaborations

Our Nexus to Life Sciences Innovation

For decades, Wilson Sonsini has advised and worked closely with life sciences industry icons who were responsible novel and ground-breaking inventions, such as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. As the industry has expanded, so has the scope of Wilson Sonsini's work with life sciences innovators, institutions, and investors. In fact, our team has represented clients in the following life sciences fields:

  • Agricultural biotechnology
  • Adoptive cell therapy
  • Animal health
  • Antibody therapeutics
  • Biochemistry
  • Bioinformatics software
  • Biomedical sciences
  • Biotechnology
  • Catalysis and oil processing
  • CAR-T cell therapies 
  • CRISPR gene editing
  • Cell therapy
  • Chemical engineering
  • Digital health
  • Diagnostics
  • Genetic engineering
  • Gene therapy
  • Genetics
  • Genome editing
  • Genomics
  • Immuno-oncology    
  • Medical devices
  • Molecular biology, RNA-based medicines
  • Nanotechnology
  • Organic and medicinal chemistry
  • Personalized medicine
  • Peptides
  • Pharmaceuticals
  • Proteomics
  • Solid state and inorganic chemistry
  • Stem cell biology
  • Small molecule therapeutics
  • Synthetic biology
  • TechBio
  • Therapeutics
  • Tissue engineering
  • Virology

Our Inter-Disciplinary Team and Comprehensive Scope of Practice

Our work with life sciences companies to help them develop and implement their business strategies encompasses:

  • Patents and Innovation Strategy – We help founders of growing life sciences companies formulate actionable business strategies focused on building and protecting robust and valuable patent portfolios, while also helping established companies protect groundbreaking discoveries.
  • Life Sciences Commercial and Technology Transactions – We represent clients in complex commercial and other technology and licensing transactions, including bet-the-company complex commercial collaborations and their foundational intellectual property licenses.
  • Corporate – We address the broad corporate needs of our life sciences clients, including helping them raise private and public capital and advising them on complicated M&A structures. The firm has represented companies in more venture financing transactions than any other U.S. law firm.
  • Healthcare and FDA Regulatory – We advise life sciences clients on regulatory strategies for their products and services, including representing them in regulatory matters before the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and other federal and state consumer protection agencies.
  • Life Sciences Business Advisory Practice – We offer business advisory capabilities that complement our firm’s legal representation. Our Business Advisory practice helps emerging and established life sciences companies execute business strategies, including crafting and enhancing their business plans; raising capital; recruiting and retaining their teams; and structuring, negotiating, and managing strategic transactions.
  • Intellectual Property Litigation – We represent life sciences companies in a broad range of IP disputes and complex litigation, including patent, trade secret, trademark, and copyright matters.
Overview

A Legacy of Life Sciences Leadership

The firm has a 60-plus year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives, which includes protecting and leveraging their most valuable IP assets. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients.

Our clients include thousands of innovation-focused life sciences companies, research institutions, start-up accelerators and incubators, and the venture capital funds and banks that finance the industry. A central pillar of our Life Sciences practice is our longstanding representation of medical device and biopharmaceutical companies, entrepreneurs, and investors, which dates back to these industries’ inception.

Wilson Sonsini’s Life Sciences practice is anchored by an inter-disciplinary team of more than 275 attorneys, patent agents, and IP professionals, many of whom hold possess Ph.Ds or other advanced degrees in biology, chemistry, biomedical sciences, or engineering. The team also includes former in-house legal counsel for major life sciences companies, an internationally recognized leader in the field of technology transfer, and former senior officials at U.S. federal agencies, such as the U.S. Patent and Trademark Office (USPTO) and the Patent Trial and Appeal Board (PTAB).

Key Points About Our Practice

On behalf of our life sciences clients, Wilson Sonsini:

  • Acted as trusted advisors to 1,800+ private and 170+ publicly traded life sciences companies
  • Completed hundreds of public offerings and M&A transactions with a combined value of more than $122.5 billion between 2020-2025
  • Raised 1,500+ venture rounds totaling over $38.1 billion
  • Counseled hundreds of life sciences companies on structuring strategic commercial collaborations

Our Nexus to Life Sciences Innovation

For decades, Wilson Sonsini has advised and worked closely with life sciences industry icons who were responsible novel and ground-breaking inventions, such as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. As the industry has expanded, so has the scope of Wilson Sonsini's work with life sciences innovators, institutions, and investors. In fact, our team has represented clients in the following life sciences fields:

  • Agricultural biotechnology
  • Adoptive cell therapy
  • Animal health
  • Antibody therapeutics
  • Biochemistry
  • Bioinformatics software
  • Biomedical sciences
  • Biotechnology
  • Catalysis and oil processing
  • CAR-T cell therapies 
  • CRISPR gene editing
  • Cell therapy
  • Chemical engineering
  • Digital health
  • Diagnostics
  • Genetic engineering
  • Gene therapy
  • Genetics
  • Genome editing
  • Genomics
  • Immuno-oncology    
  • Medical devices
  • Molecular biology, RNA-based medicines
  • Nanotechnology
  • Organic and medicinal chemistry
  • Personalized medicine
  • Peptides
  • Pharmaceuticals
  • Proteomics
  • Solid state and inorganic chemistry
  • Stem cell biology
  • Small molecule therapeutics
  • Synthetic biology
  • TechBio
  • Therapeutics
  • Tissue engineering
  • Virology

Our Inter-Disciplinary Team and Comprehensive Scope of Practice

Our work with life sciences companies to help them develop and implement their business strategies encompasses:

  • Patents and Innovation Strategy – We help founders of growing life sciences companies formulate actionable business strategies focused on building and protecting robust and valuable patent portfolios, while also helping established companies protect groundbreaking discoveries.
  • Life Sciences Commercial and Technology Transactions – We represent clients in complex commercial and other technology and licensing transactions, including bet-the-company complex commercial collaborations and their foundational intellectual property licenses.
  • Corporate – We address the broad corporate needs of our life sciences clients, including helping them raise private and public capital and advising them on complicated M&A structures. The firm has represented companies in more venture financing transactions than any other U.S. law firm.
  • Healthcare and FDA Regulatory – We advise life sciences clients on regulatory strategies for their products and services, including representing them in regulatory matters before the Food and Drug Administration (FDA), the Federal Trade Commission (FTC), and other federal and state consumer protection agencies.
  • Life Sciences Business Advisory Practice – We offer business advisory capabilities that complement our firm’s legal representation. Our Business Advisory practice helps emerging and established life sciences companies execute business strategies, including crafting and enhancing their business plans; raising capital; recruiting and retaining their teams; and structuring, negotiating, and managing strategic transactions.
  • Intellectual Property Litigation – We represent life sciences companies in a broad range of IP disputes and complex litigation, including patent, trade secret, trademark, and copyright matters.
Client Highlights
Wilson Sonsini Advises KymaThera on IP Matters Related to $80 Million Series B
On October 6, 2026, KymaThera, a biotechnology company developing next-generation precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and others. Wilson Sonsini Goodrich & Rosati advised KymaThera on intellectual property matters related to the financing.
Podcasts
NextGen VC Podcast: The Scientist Who Said Yes to Everything—and Ended Up in VC
Nandita Shangari didn’t plan to end up in venture capital. She was a toxicologist at Novartis, and said yes to one unplanned opportunity after another, until she’d worked on Kymriah (the first U.S. Food and Drug Administration-approved CAR T therapy), ran the Novartis Venture Fund, and ultimately landed at RA Capital Management, where she’s now managing director.
Client Highlights
Wilson Sonsini Advises Bambusa Therapeutics on $168.9 Million Initial Public Offering
On October 29, 2026, Bambusa Therapeutics, a Boston-based clinical-stage company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of $16.00 per share. Bambusa’s common stock began trading on the Nasdaq Global Select Market today under the ticker symbol “BBTX.” Wilson Sonsini Goodrich & Rosati advised Bambusa on the transaction.
Alerts
New COINS of the Realm: Treasury’s Implementation of COINS Act Reaches Biotech, AI, and More
On Thursday, October 22, 2026, the U.S. Department of the Treasury (Treasury) issued a notice of proposed rulemaking (the Proposed Rule) to replace and expand the current Outbound Investment Security Program (the OISP). The Proposed Rule would implement Subtitle C of the Comprehensive Outbound Investment National Security Act of 2025 (the COINS Act) enacted last December, which we previously discussed here. The Proposed Rule would establish new regulations (to be codified at 31 C.F.R. Part 851) that prohibit U.S. persons from making certain investments, and require them to notify Treasury of others, when the target is a company or other person tied to the People’s Republic of China (PRC, including Hong Kong and Macau), Cuba, Iran, North Korea, Russia, or (in specified circumstances) Venezuela (each such company or other person being a “covered foreign person”) that is engaged in specified technologies. Comments on the Proposed Rule are due December 7, 2026.
Client Highlights
Wilson Sonsini Advises Orbus Therapeutics on IP Matters Related to Acquisition by US WorldMeds
On October 27, 2026, US WorldMeds, a specialty pharmaceutical company, and Orbus Therapeutics, a privately held pharmaceutical company developing investigational eflornithine for rare and serious brain tumors, announced a definitive merger agreement under which US WorldMeds has acquired Orbus. Wilson Sonsini Goodrich & Rosati advised Orbus on IP matters in connection with the transaction.
Client Highlights
Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences
On October 22, 2026, Gilead Sciences, a biopharmaceutical company pursuing breakthroughs in medicine, announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company, for $1.275 billion in upfront cash consideration, subject to customary adjustments. The transaction is expected to close later in 2026. Wilson Sonsini Goodrich & Rosati is advising PepStar on patent matters related to the transaction.
View All
Insights
Client Highlights
Wilson Sonsini Advises KymaThera on IP Matters Related to $80 Million Series B
On October 6, 2026, KymaThera, a biotechnology company developing next-generation precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and others. Wilson Sonsini Goodrich & Rosati advised KymaThera on intellectual property matters related to the financing.
Podcasts
NextGen VC Podcast: The Scientist Who Said Yes to Everything—and Ended Up in VC
Nandita Shangari didn’t plan to end up in venture capital. She was a toxicologist at Novartis, and said yes to one unplanned opportunity after another, until she’d worked on Kymriah (the first U.S. Food and Drug Administration-approved CAR T therapy), ran the Novartis Venture Fund, and ultimately landed at RA Capital Management, where she’s now managing director.
Client Highlights
Wilson Sonsini Advises Bambusa Therapeutics on $168.9 Million Initial Public Offering
On October 29, 2026, Bambusa Therapeutics, a Boston-based clinical-stage company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of $16.00 per share. Bambusa’s common stock began trading on the Nasdaq Global Select Market today under the ticker symbol “BBTX.” Wilson Sonsini Goodrich & Rosati advised Bambusa on the transaction.
Alerts
New COINS of the Realm: Treasury’s Implementation of COINS Act Reaches Biotech, AI, and More
On Thursday, October 22, 2026, the U.S. Department of the Treasury (Treasury) issued a notice of proposed rulemaking (the Proposed Rule) to replace and expand the current Outbound Investment Security Program (the OISP). The Proposed Rule would implement Subtitle C of the Comprehensive Outbound Investment National Security Act of 2025 (the COINS Act) enacted last December, which we previously discussed here. The Proposed Rule would establish new regulations (to be codified at 31 C.F.R. Part 851) that prohibit U.S. persons from making certain investments, and require them to notify Treasury of others, when the target is a company or other person tied to the People’s Republic of China (PRC, including Hong Kong and Macau), Cuba, Iran, North Korea, Russia, or (in specified circumstances) Venezuela (each such company or other person being a “covered foreign person”) that is engaged in specified technologies. Comments on the Proposed Rule are due December 7, 2026.
Client Highlights
Wilson Sonsini Advises Orbus Therapeutics on IP Matters Related to Acquisition by US WorldMeds
On October 27, 2026, US WorldMeds, a specialty pharmaceutical company, and Orbus Therapeutics, a privately held pharmaceutical company developing investigational eflornithine for rare and serious brain tumors, announced a definitive merger agreement under which US WorldMeds has acquired Orbus. Wilson Sonsini Goodrich & Rosati advised Orbus on IP matters in connection with the transaction.
Client Highlights
Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences
On October 22, 2026, Gilead Sciences, a biopharmaceutical company pursuing breakthroughs in medicine, announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company, for $1.275 billion in upfront cash consideration, subject to customary adjustments. The transaction is expected to close later in 2026. Wilson Sonsini Goodrich & Rosati is advising PepStar on patent matters related to the transaction.
View All
Affiliated Programs
Behind the Raise: The Financial Journey for Life Science Founders
Wilson Sonsini is pleased to sponsor the University of San Diego Knauss School of Business Center for Applied Finance symposium, which will focus on the key considerations and strategies for raising capital in the early stages of building a life sciences company.
Affiliated Programs
27th Annual Berkeley-Stanford Advanced Patent Law Institute
Wilson Sonsini Goodrich & Rosati is pleased to support the 27th Annual Berkeley-Stanford Advanced Patent Law Institute, a premier program that brings together patent litigators, prosecutors, senior in-house intellectual property (IP) counsel, academics, and judges for two days of candid, practical discussion of where patent law is headed.
Affiliated Programs
Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
Wilson Sonisni is proud to sponsor Pharmaceutical & BioScience Society International (PBSS). 
Affiliated Programs
Wilson Sonsini and HBA San Francisco Bay Area Chapter Year-End Educational Networking Event
Wilson Sonsini Goodrich & Rosati is proud to sponsor the Healthcare Businesswomen’s Association (HBA).
Affiliated Programs
2026 US-Japan Healthcare Innovation Conference
Wilson Sonsini is pleased to sponsor the 2026 US-Japan Healthcare Innovation Conference.
Affiliated Programs
HLTH 2026
Wilson Sonsini will host multiple events during HLTH 2026 in Las Vegas. Please see below for details.

Digital Health Reception Sunday, November 15
7:00 - 10:00 p.m.
View All
Events
Affiliated Programs
Behind the Raise: The Financial Journey for Life Science Founders
Wilson Sonsini is pleased to sponsor the University of San Diego Knauss School of Business Center for Applied Finance symposium, which will focus on the key considerations and strategies for raising capital in the early stages of building a life sciences company.
Affiliated Programs
27th Annual Berkeley-Stanford Advanced Patent Law Institute
Wilson Sonsini Goodrich & Rosati is pleased to support the 27th Annual Berkeley-Stanford Advanced Patent Law Institute, a premier program that brings together patent litigators, prosecutors, senior in-house intellectual property (IP) counsel, academics, and judges for two days of candid, practical discussion of where patent law is headed.
Affiliated Programs
Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
Wilson Sonisni is proud to sponsor Pharmaceutical & BioScience Society International (PBSS). 
Affiliated Programs
Wilson Sonsini and HBA San Francisco Bay Area Chapter Year-End Educational Networking Event
Wilson Sonsini Goodrich & Rosati is proud to sponsor the Healthcare Businesswomen’s Association (HBA).
Affiliated Programs
2026 US-Japan Healthcare Innovation Conference
Wilson Sonsini is pleased to sponsor the 2026 US-Japan Healthcare Innovation Conference.
Affiliated Programs
HLTH 2026
Wilson Sonsini will host multiple events during HLTH 2026 in Las Vegas. Please see below for details.

Digital Health Reception Sunday, November 15
7:00 - 10:00 p.m.
View All
Ali R. Alemozafar
Partner
San Francisco
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
  • Patents and Innovations
View Profile
Matthew A. Argenti
Partner
Palo Alto
Matt is an experienced patent litigatior with an focus on post-grant review proceedings before the PTAB.
  • Litigation
View Profile
Hin Au
Partner
Palo Alto
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
  • Patents and Innovations
View Profile
Mark B. Baudler
Partner
San Francisco
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
  • Corporate
View Profile
Mark W. Bellomy
Partner
Boston
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
  • Technology Transactions
View Profile
Miranda Biven
Partner
San Diego

Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.

  • Technology Transactions
View Profile
Lance E. Brady
Partner
Palo Alto
Lance Brady is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office, where his practice focuses on representing public and private life sciences and technology companies through all stages of their growth. Lance advises his clients on a broad variety of transactions and corporate matters, including initial formation and organization, equity and debt financings, mergers and acquisitions, public offerings, spin-outs, corporate governance, SEC compliance and public company reporting requirements. He also has extensive experience representing venture capital and other institutional investors in financing transactions.
  • Corporate
View Profile
Jason Breen
Partner
Los Angeles
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.
  • Mergers & Acquisitions
View Profile
Nellie J. Brutocao
Partner
San Diego
Nellie Brutocao is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, where she advises public and private companies on structuring, negotiating, and executing complex transactions involving the development, licensing, acquisition, monetization, and commercialization of innovative technologies and therapeutics. Her experience includes negotiating bespoke strategic collaborations and licensing arrangements; advising on the intellectual property and commercial aspects of mergers, acquisitions, and divestitures; and counseling clients on critical commercial and operational agreements. Nellie brings a practical, business-oriented approach to navigating complex legal and commercial issues and developing creative solutions that advance her clients’ strategic objectives.
  • Technology Transactions
View Profile
Kassandra K. Castillo
Partner
San Diego
Kassandra K. Castillo practices corporate and securities law in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she serves as outside general counsel and advises life sciences and technology companies at all stages of development. She works closely with entrepreneurs to counsel them through initial company formation issues, day-to-day corporate governance matters, venture capital financing transactions, and liquidity events. She also counsels venture capital funds on structuring and executing investment transactions and managing their existing portfolio companies.
  • Corporate
View Profile
View All
People
Ali R. Alemozafar
Partner
San Francisco
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
  • Patents and Innovations
View Profile
Matthew A. Argenti
Partner
Palo Alto
Matt is an experienced patent litigatior with an focus on post-grant review proceedings before the PTAB.
  • Litigation
View Profile
Hin Au
Partner
Palo Alto
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
  • Patents and Innovations
View Profile
Mark B. Baudler
Partner
San Francisco
Mark is a corporate law veteran, having advised start-ups and mature public companies for more than 25 years.
  • Corporate
View Profile
Mark W. Bellomy
Partner
Boston
Mark Bellomy is a partner in Wilson Sonsini Goodrich & Rosati’s Boston office, where he is a member of the technology transactions practice. Mark advises numerous domestic and international public and private biopharmaceutical, medtech, digital health, medical device, and life sciences companies on all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to structuring and negotiating a wide range of arrangements designed to maximize the value of their businesses.
  • Technology Transactions
View Profile
Miranda Biven
Partner
San Diego

Miranda advises life sciences clients in partnering and licensing arrangements, M&A, and other transactions.

  • Technology Transactions
View Profile
Lance E. Brady
Partner
Palo Alto
Lance Brady is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office, where his practice focuses on representing public and private life sciences and technology companies through all stages of their growth. Lance advises his clients on a broad variety of transactions and corporate matters, including initial formation and organization, equity and debt financings, mergers and acquisitions, public offerings, spin-outs, corporate governance, SEC compliance and public company reporting requirements. He also has extensive experience representing venture capital and other institutional investors in financing transactions.
  • Corporate
View Profile
Jason Breen
Partner
Los Angeles
Jason Breen is a partner in the Los Angeles office of Wilson Sonsini Goodrich & Rosati, where he represents public and private companies at all stages of growth in M&A transactions, primarily working with clients in the life sciences and technology industries. Jason also represents venture capital, growth equity, and private equity funds and focuses on other strategic transactions, including divestitures, joint ventures, and financings.
  • Mergers & Acquisitions
View Profile
Nellie J. Brutocao
Partner
San Diego
Nellie Brutocao is a partner in the technology transactions practice at Wilson Sonsini Goodrich & Rosati. Her practice focuses on the life sciences industry, where she advises public and private companies on structuring, negotiating, and executing complex transactions involving the development, licensing, acquisition, monetization, and commercialization of innovative technologies and therapeutics. Her experience includes negotiating bespoke strategic collaborations and licensing arrangements; advising on the intellectual property and commercial aspects of mergers, acquisitions, and divestitures; and counseling clients on critical commercial and operational agreements. Nellie brings a practical, business-oriented approach to navigating complex legal and commercial issues and developing creative solutions that advance her clients’ strategic objectives.
  • Technology Transactions
View Profile
Kassandra K. Castillo
Partner
San Diego
Kassandra K. Castillo practices corporate and securities law in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she serves as outside general counsel and advises life sciences and technology companies at all stages of development. She works closely with entrepreneurs to counsel them through initial company formation issues, day-to-day corporate governance matters, venture capital financing transactions, and liquidity events. She also counsels venture capital funds on structuring and executing investment transactions and managing their existing portfolio companies.
  • Corporate
View Profile
View All
Related Practices
  • Corporate Life Sciences
  • Healthcare and FDA Regulatory
  • Patents and Innovations
  • Technology Transactions
  • Life Sciences Business Advisory Practice
  • Litigation
Related Industries
  • AI in Healthcare
  • Animal Health
  • Biotech
  • Digital Health
  • Global Generics
  • Medical Devices
  • Diagnostics, Life Science Tools, and Deep Tech
Recent Insights
Client Highlights
Wilson Sonsini Advises KymaThera on IP Matters Related to $80 Million Series B
On October 6, 2026, KymaThera, a biotechnology company developing next-generation precision medicines for genetically defined diseases, announced the closing of an $80 million Series B financing led by Alta Partners, with participation from Venrock, Foresite Capital, J. Wood Capital, and others. Wilson Sonsini Goodrich & Rosati advised KymaThera on intellectual property matters related to the financing.
Learn More
Podcasts
NextGen VC Podcast: The Scientist Who Said Yes to Everything—and Ended Up in VC
Nandita Shangari didn’t plan to end up in venture capital. She was a toxicologist at Novartis, and said yes to one unplanned opportunity after another, until she’d worked on Kymriah (the first U.S. Food and Drug Administration-approved CAR T therapy), ran the Novartis Venture Fund, and ultimately landed at RA Capital Management, where she’s now managing director.
Learn More
View All
Recent Events
Affiliated Programs
Behind the Raise: The Financial Journey for Life Science Founders
Wilson Sonsini is pleased to sponsor the University of San Diego Knauss School of Business Center for Applied Finance symposium, which will focus on the key considerations and strategies for raising capital in the early stages of building a life sciences company.
Learn More
Affiliated Programs
27th Annual Berkeley-Stanford Advanced Patent Law Institute
Wilson Sonsini Goodrich & Rosati is pleased to support the 27th Annual Berkeley-Stanford Advanced Patent Law Institute, a premier program that brings together patent litigators, prosecutors, senior in-house intellectual property (IP) counsel, academics, and judges for two days of candid, practical discussion of where patent law is headed.
Learn More
View All
Newsletters
2025 Mid-Year Technology and Life Sciences PIPE and RDO Report
Dive into our mid-year review of 68 PIPEs and RDOs by U.S. technology and life sciences firms between January 1 and June 30, 2025. Key findings include a decline in life sciences activity and robust strength in the technology sector.
Read the Report
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Cookie Settings
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.